Skip to content

Growth of Airways and Lung Tissues in Premature and Healthy Infants

Growth of Airways and Lung Parenchyma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00419588
Enrollment
184
Registered
2007-01-08
Start date
2006-09-30
Completion date
2019-01-31
Last updated
2020-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Bronchopulmonary Dysplasia, Infant, Premature, Diseases

Keywords

infant, premature, Bronchopulmonary dysplasia, asthma

Brief summary

The purpose of this study is to evaluate the growth of the lung and how easily gas can be taken up by the lung in healthy infants born at full term without any breathing problems and infants born prematurely.

Detailed description

SPECIFIC AIM # 1: Determine the relationship between parenchymal tissue and alveolar volume with normal lung growth early in life We hypothesize that during the first two years of life that parenchymal surface area and alveolar volume increase with somatic growth; however, the ratio of surface area to volume remains constant, while ventilation within the lung becomes more homogenous. SPECIFIC AIM # 2: Determine the pulmonary sequelae of premature birth and assess the effectiveness of early treatment strategies upon the pulmonary sequelae. We hypothesize that premature birth impedes growth and development of the lung parenchyma and the airways at a corrected-age of 1-year. In addition, initiating continuous positive airway pressure (CPAP) and a permissive ventilatory strategy in very premature infants at birth will improve lung growth and lung function compared to treatment with early surfactant and conventional ventilation.

Interventions

None listed

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Months to 24 Months
Healthy volunteers
No

Inclusion criteria

* Group 1 * full term greater than 37 weeks * Group 3 * infants born premature between 23-35 weeks of age to be tested between the ages of two to twenty four months corrected.

Exclusion criteria

* heart disease * severe developmental delays

Design outcomes

Primary

MeasureTime frameDescription
Pulmonary function Testday of testingForced Expiratory flows, single breath diffusion capacity and alveolar volume

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026